Pharvaris (PHVS) Stock Forecast & Price Target

Compare

103 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

PHVS Analyst Ratings

Moderate Buy

6 Buy

0 Hold

1 Sell

Based on 7 analysts giving stock ratings to

Pharvaris

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

PHVS Stock 12 Month Forecast

Average Price Target

$34.50

▲(49.22% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Pharvaris in the last 3 months. The average price target is $34.50 with a high forecast of $52.00 and a low forecast of $16.00. The average price target represents a 49.22% change from the last price of $23.12.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","23":"$23","33":"$33","43":"$43","53":"$53"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":52,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$52.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$34.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,23,33,43,53],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20,22.46153846153846,24.923076923076923,27.384615384615387,29.846153846153847,32.30769230769231,34.769230769230774,37.23076923076923,39.69230769230769,42.15384615384615,44.61538461538461,47.07692307692308,49.53846153846154,{"y":52,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20,21.115384615384617,22.23076923076923,23.346153846153847,24.46153846153846,25.576923076923077,26.692307692307693,27.807692307692307,28.923076923076923,30.03846153846154,31.153846153846153,32.269230769230774,33.38461538461539,{"y":34.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20,19.692307692307693,19.384615384615383,19.076923076923077,18.76923076923077,18.46153846153846,18.153846153846153,17.846153846153847,17.53846153846154,17.23076923076923,16.923076923076923,16.615384615384613,16.307692307692307,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.94,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.43,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.15,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.15,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.17,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.6,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.9,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.83,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.85,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.49,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.25,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$52.00

Average Price Target$34.50

Lowest Price Target$16.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Maxwell Skor

Morgan Stanley

$34

Buy

47.06%

Upside

Reiterated

08/22/25

Morgan Stanley Keeps Their Buy Rating on Pharvaris (PHVS)

Tazeen Ahmad

Bank of America Securities

$14→$16

Sell

-30.80%

Downside

Reiterated

08/14/25

Bank of America Securities Sticks to Their Sell Rating for Pharvaris (PHVS)These changes result in our new $16 PO (prev. $14). We reiterate our Underperform rating as we await pivotal data and seek clarity on how PHVS plans to penetrate the sticky HAE market.

Joseph Schwartz

Leerink Partners

$28

Buy

21.11%

Upside

Reiterated

08/13/25

Pharvaris' Strategic Advancements and Financial Strength Bolster Buy RatingWe are updating our model to reflect Pharvaris' (PHVS, OP) 2Q25 financial results and corporate update; RAPIDe-3 data remain on track for 4Q25, followed by CHAPTER-3 results in 2H26. The company continues to execute well across its hereditary angioedema (HAE) platform centered around deucrictibant (PHA121), an oral small-molecule antagonist of the bradykinin B2 receptor (B2R). After pulling forward the timing guidance for the RAPIDe-3 study (NCT06343779) data in the on-demand setting (HAE'd of Deucrictibant) last month, results remain on track for the fourth quarter of this year. This will position the company for a New Drug Application (NDA) submission in 1H26, with a potential launch in early 2027.

Jonathan Wolleben

Citizens JMP

$55→$52

Buy

124.91%

Upside

Reiterated

08/13/25

Pharvaris price target lowered to $52 from $55 at Citizens JMPPharvaris price target lowered to $52 from $55 at Citizens JMP

Debanjana Chatterjee

JonesTrading

$43

Buy

85.99%

Upside

Reiterated

08/13/25

Pharvaris: Buy Rating Backed by Promising Trial Milestones and Strong Financial Position

Jeff Jones

Oppenheimer

$44

Buy

90.31%

Upside

Reiterated

08/13/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Debjit Chattopadhyay

Guggenheim

$32

Buy

38.41%

Upside

Initiated

06/11/25

Pharvaris initiated with a Buy at GuggenheimPharvaris initiated with a Buy at Guggenheim

Unknown Analyst

Wedbush

Not Ranked

Wedbush

$27

Buy

16.78%

Upside

Reiterated

06/05/25

Wedbush Keeps Their Buy Rating on Pharvaris (PHVS)

Steven Seedhouse

Cantor Fitzgerald

$25

Buy

8.13%

Upside

Reiterated

05/13/25

Cantor Fitzgerald Keeps Their Buy Rating on Pharvaris (PHVS)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Maxwell Skor

Morgan Stanley

$34

Buy

47.06%

Upside

Reiterated

08/22/25

Morgan Stanley Keeps Their Buy Rating on Pharvaris (PHVS)

Tazeen Ahmad

Bank of America Securities

$14→$16

Sell

-30.80%

Downside

Reiterated

08/14/25

Joseph Schwartz

Leerink Partners

$28

Buy

21.11%

Upside

Reiterated

08/13/25

Jonathan Wolleben

Citizens JMP

$55→$52

Buy

124.91%

Upside

Reiterated

08/13/25

Pharvaris price target lowered to $52 from $55 at Citizens JMPPharvaris price target lowered to $52 from $55 at Citizens JMP

Debanjana Chatterjee

JonesTrading

$43

Buy

85.99%

Upside

Reiterated

08/13/25

Pharvaris: Buy Rating Backed by Promising Trial Milestones and Strong Financial Position

Jeff Jones

Oppenheimer

$44

Buy

90.31%

Upside

Reiterated

08/13/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Debjit Chattopadhyay

Guggenheim

$32

Buy

38.41%

Upside

Initiated

06/11/25

Pharvaris initiated with a Buy at GuggenheimPharvaris initiated with a Buy at Guggenheim

Unknown Analyst

Wedbush

Not Ranked

Wedbush

$27

Buy

16.78%

Upside

Reiterated

06/05/25

Wedbush Keeps Their Buy Rating on Pharvaris (PHVS)

Steven Seedhouse

Cantor Fitzgerald

$25

Buy

8.13%

Upside

Reiterated

05/13/25

Cantor Fitzgerald Keeps Their Buy Rating on Pharvaris (PHVS)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Pharvaris

1 Month

xxx

Success Rate

13/21 ratings generated profit

Average Return

+1.49%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 61.90% of your transactions generating a profit, with an average return of +1.49% per trade.

3 Months

xxx

Success Rate

11/19 ratings generated profit

Average Return

+3.78%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 57.89% of your transactions generating a profit, with an average return of +3.78% per trade.

1 Year

Joseph SchwartzLeerink Partners

Success Rate

15/21 ratings generated profit

Average Return

+36.89%

reiterated a buy rating 12 days ago

Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +36.89% per trade.

2 Years

xxx

Success Rate

23/27 ratings generated profit

Average Return

+53.54%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 85.19% of your transactions generating a profit, with an average return of +53.54% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PHVS Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, PHVS has received 22 Buy Ratings, 0 Hold Ratings, and 3 Sell Ratings. PHVS average Analyst price target in the past 3 months is 34.50.

Each month's total comprises the sum of three months' worth of ratings.

PHVS Financial Forecast

PHVS Earnings Forecast

Next quarter’s earnings estimate for PHVS is -$0.78 with a range of -$1.01 to -$0.70. The previous quarter’s EPS was -$0.96. PHVS beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.02% of the time in the same period. In the last calendar year PHVS has Preformed in-line its overall industry.

No data currently available

PHVS Sales Forecast

Next quarter’s sales forecast for PHVS is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. PHVS beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.16% of the time in the same period. In the last calendar year PHVS has Preformed in-line its overall industry.

PHVS Stock Forecast FAQ

What is PHVS’s average 12-month price target, according to analysts?

Based on analyst ratings, Pharvaris’s 12-month average price target is 34.50.

What is PHVS’s upside potential, based on the analysts’ average price target?

Pharvaris has 49.22% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is PHVS a Buy, Sell or Hold?

Pharvaris has a consensus rating of Moderate Buy which is based on 6 buy ratings, 0 hold ratings and 1 sell ratings.

What is Pharvaris’s price target?

The average price target for Pharvaris is 34.50. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $52.00 ,the lowest forecast is $16.00. The average price target represents 49.22% Increase from the current price of $23.12.

What do analysts say about Pharvaris?

Pharvaris’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of PHVS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Pharvaris (PHVS) Stock Forecast & Price Target

PHVS Analyst Ratings

PHVS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Pharvaris

PHVS Analyst Recommendation Trends

PHVS Financial Forecast

PHVS Earnings Forecast

PHVS Sales Forecast

PHVS Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts